INTUITIVE SURGICAL INC (ISRG)

Intuitive Surgical, Inc. designs, manufactures, and markets a comprehensive ecosystem of robotic-assisted surgical and diagnostic products, primarily its flagship da Vinci Surgical System line (X, Xi, SP, Si, S, and standard models) and the Ion endoluminal system for minimally invasive lung biopsies. The company's ecosystem integrates advanced robotic systems with a broad suite of proprietary instruments and accessories—including EndoWrist and SureForm staplers, vessel sealers, Firefly fluorescence imaging, and 3DHD vision systems—along with progressive learning pathways (Training Pathways, SimNow simulation, Intuitive Learning), comprehensive support services (maintenance, perioperative consulting, Custom Hospital Analytics), and digital tools (My Intuitive app, Intuitive Hub, Iris 3D modeling) that provide actionable insights across the surgical care continuum. Intuitive targets five surgical specialties—general surgery, urology, gynecology, cardiothoracic, and head and neck—addressing procedures such as hernia repair, colorectal surgery, cholecystectomy, bariatric surgery, prostatectomy, partial nephrectomy, hysterectomy, sacrocolpopexy, lobectomy, and transoral surgery, guided by a "quadruple aim" framework of improving patient outcomes, patient experience, care team satisfaction, and cost efficiency.

As of December 31, 2022, the company had an installed base of 7,544 da Vinci systems worldwide (4,563 in the U.S.) and 321 Ion systems (320 in the U.S.), with surgeons performing approximately 1,875,000 procedures using its technology during 2022; domestic revenue represented 67% of total revenue, with the remainder from international markets served through direct sales organizations (U.S., Europe, China, Japan, South Korea, India, Taiwan, Canada) and distributors elsewhere, including a majority-owned joint venture in China with Shanghai Fosun Pharmaceutical. The company manufactures systems in Sunnyvale, California, Durham, North Carolina, and Peachtree Corners, Georgia, and instruments in Sunnyvale and Mexicali, Mexico, with additional manufacturing in Germany, relying on both custom and off-the-shelf components from numerous suppliers, some sole- or single-sourced. Intuitive faces competition from open surgery, conventional minimally invasive surgery, drug and radiation therapies, and an expanding field of robotic-surgery competitors including Johnson & Johnson, Medtronic, CMR Surgical, and others.

The company maintains a substantial intellectual property portfolio, owning more than 4,300 granted patents and over 2,100 pending patent applications worldwide as of the end of 2022, and its products and operations are subject to U.S. regulatory oversight.